Clinical Trials News

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the "Company") today announced that it has reached an agreement for a comprehensive resolution of the remaining talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned on, among other things, the express participation of at least 95% of the remaining claims. The proposed resolution follows a favorable ruling by the MDL court, and acknowle...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Monday, August 3, 2026, at 4:30 p.m. ET,...

PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the expansion of its leadership team with the appointments of Dr. Teji Singh, M.D., as Chief Medical Officer; David Chapman as Senior Vice President of Operations; Dr. Karin Lucas, Ph.D., as Vice President of Medical Affairs; and Maggie Loeffler, CPA, as Vice President of Finance & Administration. The...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced data to be presented this week at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil, from the phase IIIb VOGUE study. Data show that Dovato (dolutegravir/lamivudine (DTG/3TC)) demonstrated non-inferior efficacy to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)) in treatment-naïve adults living with...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--LAPIX Therapeutics has appointed Abbas Kazimi, Chief Executive Officer of Nimbus Therapeutics, to its Board of Directors as the Company advances its TIM 3/4 agonist program through Phase 1b clinical trials in rheumatoid arthritis (RA) and atopic dermatitis (AD). Kazimi brings more than two decades of biotechnology leadership experience spanning company building, corporate strategy, financing, and drug development. As CEO of Nimbus Therapeutics, he has overseen...

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, a global leader in artificial intelligence-driven solutions for oncology, clinical trial matching, and patient navigation, and the Latin American Study Group on Lymphoproliferative Disorders (GELL), one of the most influential scientific and academic networks dedicated to lymphomas and hematologic malignancies in Latin America, today announced a strategic partnership focused on advancing clinical research, physician education, and innovation throu...

MANHASSET, N.Y.--(BUSINESS WIRE)--Northwell Health’s Feinstein Institutes for Medical Research has announced the groundbreaking release of the world’s first comprehensive human vagus nerve anatomical map, an achievement set to change our understanding of the autonomic nervous system and accelerate the development of bioelectronic medicine and neuromodulation therapies. The first dataset release, meticulously collected over three years from 30 human donors encompassing 60 vagus nerves, is now wi...

TORONTO--(BUSINESS WIRE)--CEO Dr. Brian Jahns presenting Pegevongitide (AV-001), Vasomune's dual-use drug candidate to the NATO NSPA CBRN Conference in Capellen, Luxembourg....

PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), announces that new data from the Phase 3 VISIONARY study will be presented at the GlomCon Hawaii 2026 conference taking place August 3-7, 2026. Building on recently reported topline results, the oral presentation will highlight key, two-year (24-month) VISIONARY estimated glomerular filtration rate (eGFR) and safety data in adults with primary IgA nephropathy (IgAN) at risk for disease pr...

NEW YORK--(BUSINESS WIRE)--Enhanced Group Inc. (NYSE: ENHA) the elite sports competition and personalized performance products company commended the United States Food & Drug Administration’s (FDA) Pharmacy Compounding Advisory Committee (PCAC) for its vote last week recommending that BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax be added to the FDA's Section 503A Bulk Drug Substances List. This recommendation is a critical step toward providing licensed U.S. compounding pharmacies a leg...